First-in-class treatment to delay onset of type 1 diabetes

View source ↗

Summary

EMA has approved Teizeild, a first-in-class therapy that delays the onset of stage 3 type 1 diabetes. The treatment also helps preserve insulin-producing beta c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Teizeild

Snippet

Teizeild significantly delays onset of stage 3 diabetes and preserves functioning of cells producing insulin